CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to improve breast cancer treatment by identifying mechanisms of resistance to drug combinations through comprehensive data analysis. By integrating various biological data, it aims to develop personalized treatment strategies and computer models to optimize drug efficacy.
Breast Cancer (BC) is the first cause of cancer-related death in women worldwide.
Breast cancer is classified into well-recognized molecular subtypes.
Despite solid pre-clinical evidence, only some patients benefit from administering drug combinations, an indication that patient and tumor heterogeneity is still present in the current stratification.
Out of the numerous possible combinations of approved drugs, only a few have been actually tried, and the choice of tested combinations has been to…
UNIVERSITETET I OSLO
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Norway, Oslo
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Norway, Trondheim
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Finland, HELSINGIN YLIOPISTO
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Erlangen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
